This Article Full Text Full Text (PDF) All Versions of this Article: 28/4/615    most recent ATVBAHA.107.158154v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Isenberg, J. S. Articles by Frazier, W. A. PubMed PubMed Citation Articles by Isenberg, J. S. Articles by Frazier, W. A.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:615.)
© 2008 American Heart Association, Inc.

Brief Reviews

CD47

A New Target in Cardiovascular Therapy

Jeff S. Isenberg; David D. Roberts; William A. Frazier

From the Laboratory of Pathology (J.S.I, D.D.R.), National Cancer Institute, National Institutes of Health, Bethesda, Md; and the Department of Biochemistry and Molecular Biophysics (W.A.F.), Washington University School of Medicine, St. Louis, Mo.

Correspondence to William A. Frazier, PhD, Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, 660 S. Euclid Ave, St. Louis, MO 63110. E-mail frazier{at}wustl.edu

CD47, originally named integrin-associated protein, is a receptor for thrombospondin-1. A number of important roles for CD47 have been defined in regulating the migration, proliferation, and survival of vascular cells, and in regulation of innate and adaptive immunity. The recent discovery that thrombospondin-1 acts via CD47 to inhibit nitric oxide signaling throughout the vascular system has given new importance and perhaps a unifying mechanism of action to these enigmatic proteins. Here we trace the development of this exciting new paradigm for CD47 function in vascular physiology.

Key Words: thrombospondin-1 • CD47 • nitric oxide • ischemia • platelet aggregation